Israeli medical diagnostics maker Check-Cap is set to initiate a pilot study in the US to assess its C-Scan System for the prevention of colorectal cancer by detecting precancerous polyps.

The company has secured approval from the Institutional Review Board (IRB) at the New York University School of Medicine to conduct the study.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

C-Scan System is a preparation-free capsule-based screening test. It comprises an ingestible ultra-low-dose X-ray capsule and software for 3D mapping of the inner lining of the colon.

“The single-arm pilot study will assess the safety, usability and subject compliance of the C-Scan System in up to 45 participants who are considered to be at average risk of developing polyps and colon cancer.”

The capsule is said to act as an integrated positioning, control and recording system. It moves through the gastrointestinal tract by natural motility.

Check-Cap CEO Alex Ovadia said: “We are excited to receive IRB approval as this important milestone enables Check-Cap to bring the C-Scan system into the clinic in the US.

“We look forward to the initiation of the pilot study evaluating our patient-friendly screening method for colorectal cancer as we aim to increase screening adherence and ultimately decrease the overall incidence for this highly-preventable disease.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The single-arm pilot study will assess the safety, usability and subject compliance of the C-Scan System in up to 45 participants who are considered to be at average risk of developing polyps and colon cancer.

Colon cancer affects the large intestine and most cases begin as small non-cancerous polyps, which can become cancerous over time and must be monitored over a patients lifetime.

Check-Cap expects to complete the study by September this year.

Check-Cap partnered with GE Healthcare in August 2016 to develop and assess the capsule-based test.

Last year, the company received the European CE-Mark clearance and the approval in Israel to begin commercial sales of the C-Scan system.

Additional reporting by Charlotte Edwards.